Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.05.2014 | case report

Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology

verfasst von: Ursula Pluschnig, MD, Hans-Jörg Neumann, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The patient described here was diagnosed with hormone-receptor-positive breast cancer and underwent numerous treatments in the neoadjuvant, adjuvant and palliative settings. Metastatic disease occurred that was confined to the bone, but kept progressing over several years. Due to the short-lasting nature of the patient’s responses to various endocrine agents, a re-biopsy was performed and a hormone receptor switch to triple negativity was established. With nab-paclitaxel therapy, disease stabilisation has been achieved for 8 months. The patient has tolerated this therapy very well in spite of massive pretreatment.
Vorheriger Artikel Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?
Literatur
1.
Hoefnagel LD, van der Groep P, van de Vijver MJ, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol. 2013;24:3017–23.PubMedCrossRef
2.
Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–8.PubMedCrossRef
3.
Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions. 1977;7:63–7.PubMedCrossRef
4.
Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263–8.PubMed
5.
ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–85.PubMedCrossRef
6.
Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–7.PubMed
7.
Winer E, Berry D, Duggan D, et al. Failure of higher-dose paclitaxel to improve outcome of patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061–8.PubMedCrossRef
8.
van Tellingen O, Huizing MT, Panday VR, et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81:330–5.PubMedCentralPubMedCrossRef
9.
10.
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.PubMedCrossRef
11.
Pusztai L, Viale G, Kelly CM, et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15(11):1164–8.PubMedCentralPubMedCrossRef
12.
Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013;18:667–74.PubMedCentralPubMedCrossRef
13.
Chen S, Chen CM, Yu KD, et al. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012;19(9):3002–11.PubMedCrossRef
14.
Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12(6):R92.PubMedCentralPubMedCrossRef
Metadaten
Titel
Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology
verfasst von
Ursula Pluschnig, MD
Hans-Jörg Neumann, MD
Publikationsdatum
01.05.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0147-7

Weitere Artikel der Ausgabe 2/2014

An academic pathological dilemma

  • editorial

Follow-up for patients with malignancies after radical treatment: unresolved questions

  • editorial

Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?

  • short review

Follow-up in soft tissue sarcomas

  • Open Access
  • short review

Follow-up in aggressive lymphomas

  • short review

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma

  • short review